Biocytogen Pharmaceuticals, a global biotechnology company focused on the development of novel antibody therapeutics, and ABL Bio Inc. (“ABL”, KOSDAQ: 298380), a Korean clinical-stage biotechnology company developing novel therapeutics in in oncology and for the treatment of CNS diseases, today announced their collaboration to develop new bispecific antibody-drug conjugates (bsADCs).
Biocytogen’s RenLite mouse platform can produce fully human antibodies with diverse epitopes and high affinity. This platform is distinguished by its ability to generate antibodies in a common light chain format, offering a distinctive combination of design flexibility, simplified manufacturing processes and optimal engineerability for the development of bsADCs. Based on this platform, both companies will be able to discuss expanding their collaboration for different types of antibody-drug conjugate development.
Dr. Yuelei Shen, President and CEO of Biocytogen, stated: “ We are extremely pleased to collaborate with ABL, a company that has advanced platforms for cancer immunotherapy and the treatment of CNS diseases. ABL’s consistent success in advancing its pipeline strongly demonstrates its expertise and capabilities in regulatory and clinical development as well as business development activities. BsADC drugs derived from our RenLite ® mouse platform demonstrated better potency in different tumor models while also exhibiting good safety profiles. We believe our fully human bsADC platform technology, which provides enhanced tumor selectivity, target-synergized internalization and convenient CMC development, will effectively complement ABL’s capabilities. Our shared goal is to advance the development of innovative bsADC therapies.”
Sang Hoon Lee, CEO of ABL, commented: “ We are extremely pleased to establish this partnership with Biocytogen for bsADCs. This collaboration provides a good basis for the development of bsADCs. We look forward to a productive collaboration and firmly believe that this partnership will help create a distinctive pipeline that improves the quality of life for patients.”
Biocytogen (HKEX: 02315) is a global biotechnology company that advances the discovery and development of novel antibody-based medicines using innovative technologies. Based on gene editing technology, Biocytogen utilizes genetically engineered, proprietary RenMice ® (RenMab TM /RenLite ® /RenNano ® /RenTCR-mimic TM ) platforms for the discovery of fully human monoclonal/bispecific/multispecific antibodies, bispecific antibody-drug conjugates , nanobodies and TCR-mimic antibodies and has established its RenBiologics TM sub-brand to explore global partnerships for a standard library of over 400,000 fully human antibody sequences against approximately 1000 targets for global collaboration. As of June 30, 2023, 50 therapeutic antibody and multiple clinical agent co-development, out-licensing and transfer agreements, as well as 42 targeted RenMice ® licensing projects have been concluded worldwide, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of humanized knock-in models for preclinical research. The company currently offers several thousand commercial animal and cell models as well as preclinical pharmacology and gene editing services to customers worldwide under its sub-brand BioMice TM . Biocytogen is headquartered in Beijing and has offices in China (Haimen Jiangsu, Shanghai), the USA (Boston, San Francisco) and Germany (Heidelberg).
SOURCE: Businesswire